# Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

> **NCT03291288** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 32 (actual)

## Conditions studied

- Drug Interaction Potential

## Interventions

- **DRUG:** Tolbutamide
- **DRUG:** Midazolam
- **DRUG:** Pexidartinib

## Key facts

- **NCT ID:** NCT03291288
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-26
- **Primary completion:** 2018-09-26
- **Final completion:** 2021-04-16
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03291288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03291288, "Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03291288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*